Ardelyx (NASDAQ:ARDX) Insider Eric Duane Foster Sells 8,562 Shares of Stock

Ardelyx, Inc. (NASDAQ:ARDX) insider Eric Duane Foster sold 8,562 shares of Ardelyx stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $3.86, for a total transaction of $33,049.32. Following the completion of the sale, the insider owned 409,410 shares in the company, valued at approximately $1,580,322.60. This represents a 2.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Ardelyx Trading Up 1.1%

Ardelyx stock opened at $3.78 on Wednesday. Ardelyx, Inc. has a 52-week low of $3.72 and a 52-week high of $8.40. The company has a quick ratio of 3.15, a current ratio of 3.34 and a debt-to-equity ratio of 1.69. The firm has a market capitalization of $941.94 million, a price-to-earnings ratio of -17.18 and a beta of 0.70. The firm has a 50-day moving average price of $4.97 and a two-hundred day moving average price of $5.75.

Ardelyx (NASDAQ:ARDX) last announced its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The firm had revenue of $120.88 million during the quarter, compared to analyst estimates of $121.03 million. Ardelyx had a negative net margin of 12.35% and a negative return on equity of 36.00%. Ardelyx’s revenue for the quarter was up 34.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.08) EPS. Sell-side analysts expect that Ardelyx, Inc. will post -0.2 earnings per share for the current year.

Trending Headlines about Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Despite the negative signals below, the stock has increased modestly, suggesting buyers have so far absorbed the recent selling pressure.
• Neutral Sentiment: Reported short-interest data showed zero shares short and a zero-day days-to-cover ratio, while also describing the change as a “large increase.” Because the figures are internally inconsistent, they provide no reliable signal for ARDX.
• Negative Sentiment: Eight Ardelyx insiders sold a combined 126,059 shares for approximately $486,588 at an average price of $3.86 on August 21. The sales included CEO Michael Raab, who sold 58,574 shares, and CFO Susan Hohenleitner, who sold 1,558 shares. The transactions reduced each insider’s holdings, though all retained substantial positions. CEO insider sale filing
• Negative Sentiment: Options traders purchased 11,731 put contracts on Tuesday, roughly 328% above the average volume of 2,743 contracts. The surge indicates increased hedging or bearish speculation around Ardelyx, although options activity alone does not confirm a fundamental deterioration.

Analyst Ratings Changes

ARDX has been the topic of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of Ardelyx in a research note on Friday, August 7th. TD Cowen lowered their price target on Ardelyx from $13.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 7th. Citigroup cut their price objective on shares of Ardelyx from $14.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. LADENBURG THALM/SH SH started coverage on shares of Ardelyx in a report on Tuesday, June 16th. They issued a “buy” rating and a $16.00 price objective for the company. Finally, Weiss Ratings lowered shares of Ardelyx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 29th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $13.90.

Institutional Investors Weigh In On Ardelyx

Institutional investors have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. bought a new position in Ardelyx during the 2nd quarter valued at $35,000. SCS Capital Management LLC bought a new stake in shares of Ardelyx in the 2nd quarter worth $52,000. ADAR1 Capital Management LLC bought a new stake in shares of Ardelyx in the 2nd quarter worth $56,000. Krilogy Financial LLC acquired a new stake in shares of Ardelyx in the first quarter valued at $70,000. Finally, PVG Asset Management Corp acquired a new stake in shares of Ardelyx in the first quarter valued at $65,000. 58.92% of the stock is currently owned by institutional investors and hedge funds.

Ardelyx Company Profile

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.